Regulation of anthrax toxin-specific antibody titers by natural killer T cell-derived IL-4 and IFNγ

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Devera, T Scott ^a   Joshi, Sunil K ^a   Aye, Lindsay M ^a   Lang, Gillian A ^a   Ballard, Jimmy D ^a   Lang, Mark L ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; ANTHRAX TOXIN; ANTIGEN; CD1D ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2B ANTIBODY; IMMUNOGLOBULIN G2C ANTIBODY; INTERLEUKIN 4; PROTECTIVE ANTIGEN; UNCLASSIFIED DRUG; ANTIBODY; BACTERIAL ANTIGEN; BACTERIAL TOXIN; GLYCOLIPID; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; TETRACOSANOIC ACID 1 GALACTOPYRANOSYLOXY 3,4 DIHYDROXYDEC 2 YL AMIDE; TETRACOSANOIC ACID 1-GALACTOPYRANOSYLOXY-3,4-DIHYDROXYDEC-2-YL AMIDE;

ANIMAL CELL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; BONE MARROW CELL; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NATURAL KILLER T CELL; NONHUMAN; SERODIAGNOSIS; TH1 CELL; TH2 CELL; ANIMAL; BLOOD; C57BL MOUSE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE MUTANT;

MUS;

ANIMALS; ANTIBODIES; ANTIBODIES, NEUTRALIZING; ANTIGENS, BACTERIAL; ANTIGENS, CD1D; BACTERIAL TOXINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOLIPIDS; IMMUNIZATION; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-4; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NATURAL KILLER T-CELLS; TH2 CELLS;

EID: 80051759304     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023817     Document Type: Article

References (41)

1. Bradley KA, Mogridge J, Mourez M, Collier RJ, Young JA, (2001) Identification of the cellular receptor for anthrax toxin. Nature 414: 225-229.
2. Collier RJ, Young JA, (2003) Anthrax toxin. Annu Rev Cell Dev Biol 19: 45-70.
3. Leppla SH, (1984) Bacillus anthracis calmodulin-dependent adenylate cyclase: chemical and enzymatic properties and interactions with eucaryotic cells. Adv Cyclic Nucleotide Protein Phosphorylation Res 17: 189-198.
4. Fink SL, Bergsbaken T, Cookson BT, (2008) Anthrax lethal toxin and Salmonella elicit the common cell death pathway of caspase-1-dependent pyroptosis via distinct mechanisms. Proc Natl Acad Sci U S A 105: 4312-4317.
5. Mock M, Mignot T, (2003) Anthrax toxins and the host: a story of intimacy. Cell Microbiol 5: 15-23.
6. Agrawal A, Lingappa J, Leppla SH, Agrawal S, Jabbar A, et al. (2003) Impairment of dendritic cells and adaptive immunity by anthrax lethal toxin. Nature 424: 329-334.
7. Paccani SR, Tonello F, Ghittoni R, Natale M, Muraro L, et al. (2005) Anthrax toxins suppress T lymphocyte activation by disrupting antigen receptor signaling. J Exp Med 201: 325-331.
8. Fang H, Xu L, Chen TY, Cyr JM, Frucht DM, (2006) Anthrax lethal toxin has direct and potent inhibitory effects on B cell proliferation and immunoglobulin production. J Immunol 176: 6155-6161.
9. Joshi SK, Lang GA, Larabee JL, Devera TS, Aye LM, et al. (2009) Bacillus anthracis lethal toxin disrupts TCR signaling in CD1d-restricted NKT cells leading to functional anergy. PLoS Pathog 5: e1000588.
10. Abboud N, Casadevall A, (2008) Immunogenicity of Bacillus anthracis protective antigen domains and efficacy of elicited antibody responses depend on host genetic background. Clin Vaccine Immunol 15: 1115-1123.
11. Boyaka PN, Tafaro A, Fischer R, Leppla SH, Fujihashi K, et al. (2003) Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J Immunol 170: 5636-5643.
12. Park YS, Lee JH, Hung CF, Wu TC, Kim TW, (2008) Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant. Infect Immun 76: 1952-1959.
13. Peachman KK, Rao M, Alving CR, Burge R, Leppla SH, et al. (2006) Correlation between lethal toxin-neutralizing antibody titers and protection from intranasal challenge with Bacillus anthracis Ames strain spores in mice after transcutaneous immunization with recombinant anthrax protective antigen. Infect Immun 74: 794-797.
14. Rivera J, Nakouzi A, Abboud N, Revskaya E, Goldman D, et al. (2006) A monoclonal antibody to Bacillus anthracis protective antigen defines a neutralizing epitope in domain 1. Infect Immun 74: 4149-4156.
15. Welkos S, Little S, Friedlander A, Fritz D, Fellows P, (2001) The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology 147: 1677-1685.
16. Quinn CP, Dull PM, Semenova V, Li H, Crotty S, et al. (2004) Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax. J Infect Dis 190: 1228-1236.
17. Pittman PR, Leitman SF, Oro JG, Norris SL, Marano NM, et al. (2005) Protective antigen and toxin neutralization antibody patterns in anthrax vaccinees undergoing serial plasmapheresis. Clin Diagn Lab Immunol 12: 713-721.
18. Devera TS, Aye LM, Lang GA, Joshi SK, Ballard JD, et al. (2010) CD1d-dependent B-cell help by NK-like T cells leads to enhanced and sustained production of Bacillus anthracis lethal toxin-neutralizing antibodies. Infect Immun 78: 1610-1617.
19. Belperron AA, Dailey CM, Bockenstedt LK, (2005) Infection-induced marginal zone B cell production of Borrelia hermsii-specific antibody is impaired in the absence of CD1d. J Immunol 174: 5681-5686.
20. Devera TS, Shah HB, Lang GA, Lang ML, (2008) Glycolipid-activated NKT cells support the induction of persistent plasma cell responses and antibody titers. Eur J Immunol 38: 1001-1011.
21. Ko SY, Ko HJ, Chang WS, Park SH, Kweon MN, et al. (2005) alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J Immunol 175: 3309-3317.
22. Lang GA, Devera TS, Lang ML, (2008) Requirement for CD1d expression by B cells to stimulate NKT cell-enhanced antibody production. Blood 111: 2158-2162.
23. Lang GA, Exley MA, Lang ML, (2006) The CD1d-binding glycolipid alpha-galactosylceramide enhances humoral immunity to T-dependent and T-independent antigen in a CD1d-dependent manner. Immunology 119: 116-125.
24. Kronenberg M, (2005) Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 23: 877-900.
25. Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H, (2003) The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol 21: 483-513.
26. Schmieg J, Yang G, Franck RW, Tsuji M, (2003) Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-Galactosylceramide. J Exp Med 198: 1631-1641.
27. Li X, Fujio M, Imamura M, Wu D, Vasan S, et al. (2010) Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. Proc Natl Acad Sci U S A 107: 13010-13015.
28. Salles II, Voth DE, Ward SC, Averette KM, Tweten RK, et al. (2006) Cytotoxic activity of Bacillus anthracis protective antigen observed in a macrophage cell line overexpressing ANTXR1. Cell Microbiol 8: 1272-1281.
29. Nguyen ML, Terzyan S, Ballard JD, James JA, Farris AD, (2009) The major neutralizing antibody responses to recombinant anthrax lethal and edema factors are directed to non-cross-reactive epitopes. Infect Immun 77: 4714-4723.
30. Nguyen ML, Crowe SR, Kurella S, Teryzan S, Cao B, et al. (2009) Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies. Infect Immun 77: 162-169.
31. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, et al. (1997) CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278: 1626-1629.
32. Lang GA, Maltsev SD, Besra GS, Lang ML, (2004) Presentation of alpha-galactosylceramide by murine CD1d to natural killer T cells is facilitated by plasma membrane glycolipid rafts. Immunology 112: 386-396.
33. Devera TS, Aye LM, Lang GA, Joshi SK, Ballard JD, et al. (2010) CD1d-dependent B cell help by NKT cells leads to enhanced and sustained production of Bacillus anthracis lethal toxin-neutralizing antibodies. Infect Immun.78: 1610-1617.
34. Martin RM, Brady JL, Lew AM, (1998) The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice. J Immunol Methods 212: 187-192.
35. Mizuno M, Masumura M, Tomi C, Chiba A, Oki S, et al. (2004) Synthetic glycolipid OCH prevents insulitis and diabetes in NOD mice. J Autoimmun 23: 293-300.
36. Oki S, Tomi C, Yamamura T, Miyake S, (2005) Preferential T(h)2 polarization by OCH is supported by incompetent NKT cell induction of CD40L and following production of inflammatory cytokines by bystander cells in vivo. Int Immunol 17: 1619-1629.
37. Williamson ED, Beedham RJ, Bennett AM, Perkins SD, Miller J, et al. (1999) Presentation of protective antigen to the mouse immune system: immune sequelae. J Appl Microbiol 87: 315-317.
38. Mohamed N, Li J, Ferreira CS, Little SF, Friedlander AM, et al. (2004) Enhancement of anthrax lethal toxin cytotoxicity: a subset of monoclonal antibodies against protective antigen increases lethal toxin-mediated killing of murine macrophages. Infect Immun 72: 3276-3283.
39. Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE, (1999) The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol 17: 701-738.
40. Szabo SJ, Sullivan BM, Peng SL, Glimcher LH, (2003) Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol 21: 713-758.
41. Abboud N, Chow SK, Saylor C, Janda A, Ravetch JV, et al. (2010) A requirement for FcgammaR in antibody-mediated bacterial toxin neutralization. J Exp Med 207: 2395-2405.